We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

16 hedge funds and large institutions have $2.35M invested in Evoke Pharma in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

85% more capital invested

Capital invested by funds: $1.27M → $2.35M (+$1.08M)

0% less ownership

Funds ownership: 0.04% → 0.04% (-0%)

11% less funds holding

Funds holding: 18 → 16 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
16
Holders Change
-2
Holders Change %
-11.11%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$51.4K
2
CAN
Cetera Advisor Networks
California
+$4.28K
3
UBS Group
UBS Group
Switzerland
+$3.77K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$3.08K
5
BlackRock
BlackRock
New York
+$1.2K

Top Sellers

Rank Fund Capital Flow
1
ARTA
A.R.T. Advisors
New York
-$32K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$25K
3
Jane Street
Jane Street
New York
-$11K
4
Victory Capital Management
Victory Capital Management
Texas
-$3K
5
WA
Wambolt & Associates
Colorado
-$1.37K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$782K – – –
SOMRS
2
State of Michigan Retirement System
Michigan
$648K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$327K +$3.08K +18 +1%
Creative Planning
4
Creative Planning
Kansas
$162K – – –
BlackRock
5
BlackRock
New York
$91K +$1.2K +7 +2%
VF
6
Virtu Financial
New York
$70K +$51.4K +300 New
California Public Employees Retirement System
7
California Public Employees Retirement System
California
$59K – – –
Northern Trust
8
Northern Trust
Illinois
$55K – – –
WA
9
Wambolt & Associates
Colorado
$52K -$1.37K -8 -3%
Commonwealth Equity Services
10
Commonwealth Equity Services
Massachusetts
$52K – – –
UCFA
11
United Capital Financial Advisors
Texas
$25K – – –
CAN
12
Cetera Advisor Networks
California
$22K +$4.28K +25 +36%
UBS Group
13
UBS Group
Switzerland
$5K +$3.77K +22 New
LC
14
Lindbrook Capital
California
$2K – – –
Morgan Stanley
15
Morgan Stanley
New York
$2K – – –
Citigroup
16
Citigroup
New York
$1K – – –
ARTA
17
A.R.T. Advisors
New York
– -$32K -257 Closed
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
– -$25K -205 Closed
Jane Street
19
Jane Street
New York
– -$11K -87 Closed
Victory Capital Management
20
Victory Capital Management
Texas
– -$3K -26 Closed

EVOK Hedge Fund Activity: Q4 2019 in Review

16 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2019, worth a combined $2.35M — up 85% from $1.27M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of EVOK and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 3 added.

The largest buyer was Virtu Financial, opening a new position worth an estimated $51.4K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $32K sold.

  • 16 institutional investors held Evoke Pharma (EVOK) as of Q4 2019, down from 18 in Q3 2019.
  • Funds reported $2.35M of Evoke Pharma stock for Q4 2019, up 85% quarter-over-quarter.
  • 2 funds opened new Evoke Pharma positions in Q4 2019 and 4 closed out, a net change of -2 holders.
  • The largest Evoke Pharma buyer in Q4 2019 was Virtu Financial, an estimated $51.4K added.
  • The largest Evoke Pharma seller in Q4 2019 was A.R.T. Advisors, an estimated $32K sold.

Based on aggregated 13F filings for Q4 2019.